Compelling Clinical Data Released for Carlsmed’s aprevo® Technology
08 Jan 2024
CARLSBAD, Calif.--(BUSINESS WIRE)-- Carlsmed announced today that new clinical data on its aprevo® technology has been published in the Global Spine Journal. This landmark study of a patient-matched cohort concluded that the use of aprevo® personalized interbody devices enables a significant improvement in achieving alignment. The study measured the difference in pelvic incidence (PI) and lumbar lordosis (LL), referred to as PI-LL mismatch, comparing personalized spine surgery and traditional spine surgery. Prior studies have shown that achieving optimal alignment during spine fusion surgery is highly correlated with reduced complications.
Justin Smith, MD, PhD, the lead author, said, “In the publication, data is provided indicating that utilization of aprevo® patient-specific devices resulted in a 42% improvement in achieving PI-LL mismatch within 5° of the surgeons’ pre-operative plans.” The publication, Analysis of Personalized Interbody Implants in the Surgical Treatment of Adult Spinal Deformity, is available at .
“The mounting clinical evidence supports that AI-enabled personalized surgery improves outcomes and is transforming the standard of care for millions of patients in need,” said Mike Cordonnier, CEO of Carlsmed. “We will continue to advance the mission of personalization of healthcare and build awareness of the availability of this technology to patients worldwide.”
About Carlsmed
Carlsmed’s mission is to improve outcomes and decrease the cost of healthcare for spine surgery. The Carlsmed aprevo® personalized surgery platform is designed to improve the standard of care for spine surgery, one patient at a time. Carlsmed’s implantable devices and software platforms are FDA-cleared for lumbar spine fusion. Carlsmed’s proprietary digital production system enables the design and production of custom-made, anatomically designed aprevo® devices to be created on demand and delivered sterile packed to the hospital in time for surgery.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.